Summary

Global Atopic Dermatitis Drugs Market is valued at approximately USD 12.71 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 9.0% over the forecast period 2022-2029. Atopic dermatitis also known as eczema is a chronic, inflammatory skin, and non-contagious condition which affects the skin and leads to red, dry, itchy, and bumpy. The rise in awareness regarding the product availability for the disease, and robust product portfolio, coupled with the increasing expenditure on healthcare services and products are bolstering the market demand worldwide.

The rising incidences of atopic dermatitis is propelling the market demand across the globe. The Acta Derm Venereological Journal reported that in 2020 the doctor diagnosed that the prevalence of atopic dermatitis in adults varied from 17.1% in Europe to 10.2% in Asia; in children, the rates were 22.6% and 0.96%, respectively. Thereby, the high incidences of atopic dermatitis among the population are reinforcing the need for atopic dermatitis drugs to receive timely and suitable treatment, which, in turn, augments the growth of the market. Moreover, increasing product approvals, as well as the growing R&D investments by the key market players present various lucrative opportunities over the forecasting years. However, the high cost of therapeutics and some side effects associated with drugs are hindering the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Atopic Dermatitis Drugs Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the growing R&D investment and presence of well-established healthcare infrastructure. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the increase in pro-health initiatives, rise in consumer awareness, as well as strong healthcare reimbursement systems in the market space.

Major market players included in this report are:
Pfizer Inc.
Sanofi
AbbVie Inc.
GALDERMA LABORATORIES, L.P.
Eli Lilly and Company (Dermira)
Regeneron Pharmaceuticals Inc.
LEO Pharma Inc.
Otsuka Pharmaceutical Co., Ltd.
Novartis AG
Incyte Corporation

Recent Developments in the Market:
 In April 2021, AbbVie declared that the company is strengthening its supplemental New Drug Application (sNDA) to review RINVOQ for atopic dermatitis adolescent and adult patients. The Prescription Drug User Fee Act (PDUFA) was extended till quarter 3 of 2021.


Global Atopic Dermatitis Drugs Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Class, Route of Administration, , Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*




The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Class:
Corticosteroids
Calcineurin Inhibitors
PDE4 Inhibitors
Biologics
Others
By Route of Administration:
Topical
Injectable
Oral

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

ページTOPに戻る

Table of Contents

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Atopic Dermatitis Drugs Market, by Region, 2019-2029 (USD Billion)
1.2.2. Atopic Dermatitis Drugs Market, by Class, 2019-2029 (USD Billion)
1.2.3. Atopic Dermatitis Drugs Market, by Route of Administration, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Atopic Dermatitis Drugs Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Atopic Dermatitis Drugs Market Dynamics
3.1. Atopic Dermatitis Drugs Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Robust product portfolio
3.1.1.2. Increasing incidences of atopic dermatitis
3.1.2. Market Challenges
3.1.2.1. High cost of therapeutics
3.1.2.2. Some side-effects associated with drugs
3.1.3. Market Opportunities
3.1.3.1. Increasing product approvals
3.1.3.2. Growing R&D investments by the key market players
Chapter 4. Global Atopic Dermatitis Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Atopic Dermatitis Drugs Market, by Class
6.1. Market Snapshot
6.2. Global Atopic Dermatitis Drugs Market by Class, Performance - Potential Analysis
6.3. Global Atopic Dermatitis Drugs Market Estimates & Forecasts by Class 2019-2029 (USD Billion)
6.4. Atopic Dermatitis Drugs Market, Sub Segment Analysis
6.4.1. Corticosteroids
6.4.2. Calcineurin Inhibitors
6.4.3. PDE4 Inhibitors
6.4.4. Biologics
6.4.5. Others
Chapter 7. Global Atopic Dermatitis Drugs Market, by Route of Administration
7.1. Market Snapshot
7.2. Global Atopic Dermatitis Drugs Market by Route of Administration, Performance - Potential Analysis
7.3. Global Atopic Dermatitis Drugs Market Estimates & Forecasts by Route of Administration 2019-2029 (USD Billion)
7.4. Atopic Dermatitis Drugs Market, Sub Segment Analysis
7.4.1. Topical
7.4.2. Injectable
7.4.3. Oral
Chapter 8. Global Atopic Dermatitis Drugs Market, Regional Analysis
8.1. Atopic Dermatitis Drugs Market, Regional Market Snapshot
8.2. North America Atopic Dermatitis Drugs Market
8.2.1. U.S. Atopic Dermatitis Drugs Market
8.2.1.1. Class breakdown estimates & forecasts, 2019-2029
8.2.1.2. Route of Administration breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Atopic Dermatitis Drugs Market
8.3. Europe Atopic Dermatitis Drugs Market Snapshot
8.3.1. U.K. Atopic Dermatitis Drugs Market
8.3.2. Germany Atopic Dermatitis Drugs Market
8.3.3. France Atopic Dermatitis Drugs Market
8.3.4. Spain Atopic Dermatitis Drugs Market
8.3.5. Italy Atopic Dermatitis Drugs Market
8.3.6. Rest of Europe Atopic Dermatitis Drugs Market
8.4. Asia-Pacific Atopic Dermatitis Drugs Market Snapshot
8.4.1. China Atopic Dermatitis Drugs Market
8.4.2. India Atopic Dermatitis Drugs Market
8.4.3. Japan Atopic Dermatitis Drugs Market
8.4.4. Australia Atopic Dermatitis Drugs Market
8.4.5. South Korea Atopic Dermatitis Drugs Market
8.4.6. Rest of Asia Pacific Atopic Dermatitis Drugs Market
8.5. Latin America Atopic Dermatitis Drugs Market Snapshot
8.5.1. Brazil Atopic Dermatitis Drugs Market
8.5.2. Mexico Atopic Dermatitis Drugs Market
8.5.3. Rest of Latin America Atopic Dermatitis Drugs Market
8.6. Rest of The World Atopic Dermatitis Drugs Market

Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Pfizer Inc.
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Sanofi
9.2.3. AbbVie Inc.
9.2.4. GALDERMA LABORATORIES, L.P.
9.2.5. Eli Lilly and Company (Dermira)
9.2.6. Regeneron Pharmaceuticals Inc.
9.2.7. LEO Pharma Inc.
9.2.8. Otsuka Pharmaceutical Co., Ltd.
9.2.9. Novartis AG
9.2.10. Incyte Corporation
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption